Reisman D, Thompson E A
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77550-0645, USA.
Mol Endocrinol. 1995 Nov;9(11):1500-9. doi: 10.1210/mend.9.11.8584027.
Glucocorticoids cause G0/G1 arrest of lymphoid cells. This is due, at least in part, to a decrease in the abundance of the G1 progression factor, cyclin D3. The mRNA encoding cyclin D3 (CcnD3 mRNA) is rapidly down-regulated when dexamethasone is added to P1798 murine T lymphoma cells. Fifty percent maximum inhibition is observed within about 2 h. Maximum inhibition of 75-85% obtains within 4-5 h. Cyclin D3 protein has a half-life of about 0.5 h in P1798 cells. Consequently, the abundance of cyclin D3 protein decreases in parallel with the abundance of CcnD3 mRNA. The effects of glucocorticoids are reversible. CcnD3 mRNA returns to near control levels within 2-3 h after removal of dexamethasone. Cyclin D3 protein recovers somewhat more slowly. The data indicate that glucocorticoids regulate the abundance of cyclin D3 mRNA. There is no significant decrease in nuclear run-on transcription of CcnD3 within 6 h after addition of glucocorticoids, although transcription is inhibited more than 80% after 24 h in the presence of dexamethasone. CcnD3 mRNA is very stable in mid-log phase P1798 cells, with a half-life of more than 8 h. The half-life of CcnD3 mRNA in glucocorticoid-treated cells is less than 1 h. Actinomycin D blocks the effects of glucocorticoids, suggesting that dexamethasone induces a substance that increases the turnover rate of CcnD3 mRNA. Regulation of CcnD3 mRNA abundance and of CcnD3 transcription has been studied in cells arrested at the G1/S interface by thymidine blockade. Glucocorticoids down-regulate CcnD3 mRNA in the absence of cell cycle progression. This observation indicates that glucocorticoid inhibition of cyclin D3 expression is not a secondary consequence of cell cycle arrest. However, glucocorticoids have no significant effect on transcription of CcnD3 in G1/S phase-arrested cells. Inhibition of transcription of CcnD3 is a delayed response and probably reflects withdrawal into a G0 state, rather than any proximal consequence of glucocorticoid action. Destabilization of CcnD3 mRNA appears to be a direct effect of glucocorticoids, independent of cell cycle progression, and mediated by a glucocorticoid-induced protein(s) that accelerates the degradation of CcnD3 mRNA.
糖皮质激素可导致淋巴细胞停滞于G0/G1期。这至少部分是由于G1期进展因子细胞周期蛋白D3(cyclin D3)的丰度降低所致。当将地塞米松添加到P1798小鼠T淋巴瘤细胞中时,编码细胞周期蛋白D3的mRNA(CcnD3 mRNA)会迅速下调。在约2小时内可观察到最大抑制率的50%。在4 - 5小时内最大抑制率可达75 - 85%。在P1798细胞中,细胞周期蛋白D3蛋白的半衰期约为0.5小时。因此,细胞周期蛋白D3蛋白的丰度与CcnD3 mRNA的丰度平行下降。糖皮质激素的作用是可逆的。去除地塞米松后,CcnD3 mRNA在2 - 3小时内恢复到接近对照水平。细胞周期蛋白D3蛋白的恢复则稍慢一些。数据表明糖皮质激素可调节CcnD3 mRNA的丰度。添加糖皮质激素后6小时内,CcnD3的核转录延伸无显著下降,不过在存在地塞米松的情况下,24小时后转录被抑制超过80%。CcnD3 mRNA在对数中期的P1798细胞中非常稳定,半衰期超过8小时。在糖皮质激素处理的细胞中,CcnD3 mRNA的半衰期小于1小时。放线菌素D可阻断糖皮质激素的作用,这表明地塞米松诱导了一种可增加CcnD3 mRNA周转率的物质。在通过胸苷阻断停滞于G1/S期界面的细胞中,对CcnD3 mRNA丰度和CcnD3转录的调控进行了研究。在细胞周期无进展的情况下,糖皮质激素可下调CcnD3 mRNA。这一观察结果表明,糖皮质激素对细胞周期蛋白D3表达的抑制并非细胞周期停滞的继发后果。然而,糖皮质激素对G1/S期停滞细胞中CcnD3的转录无显著影响。CcnD3转录的抑制是一种延迟反应,可能反映了细胞进入G0状态,而非糖皮质激素作用的任何近端后果。CcnD3 mRNA的去稳定似乎是糖皮质激素的直接作用,与细胞周期进展无关,且由一种糖皮质激素诱导的蛋白介导,该蛋白加速了CcnD3 mRNA的降解。